Irritable Bowel Syndrome (IBS) Treatment Market Research Report - Americas Forecast till 2027

Irritable Bowel Syndrome (IBS) Treatment Market Information: By Types, (IBS-D, IBS-C, And IBS-M), By Drugs Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, And Others), By End Users (Hospitals, Clinics, And Research Laboratories) - Americas Forecast Till 2027

ID: MRFR/Pharma/4107-CR | February 2018 | Region: Americas | 69 pages

Market Scenario


Irritable bowel syndrome (IBS) is a common disorder that affects the digestive system. IBS is characterized by symptoms such as stomach cramps, bloating, diarrhea, and constipation, which impacts one’s everyday life. Although the cause of IBS is unknown, but few factors that cause IBS are severe infection, inflammation in the intestines, muscle contractions in the intestine, changes in bacteria in the gut, and abnormalities in the nerves. Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle in Americas are the key drivers of the Americas Irritable bowel syndrome (IBS) treatment market. Moreover, strong clinical pipeline and government support is fuelling the market in this region. According to an updated report by the Anxiety and Depression Association of America, in 2017, the most common mental disorder was anxiety in the United States, affecting approximately 40 million adults over 18 years every year. Additionally, According to a report of the National Institute of Mental Health, in 2015, approximately 16.1 adults over 18 years in the United States had at least one major depressive episode in the past one year, which is 6.7% of all the U.S. adults. These number generate the huge demand for better treatment in this region.


Hence, most of the companies are more into mergers, acquisitions, and collaboration activities in order to provide better treatment procedures. In this regard, Allergan Plc. in January 2017, entered into a licensing agreement with Assembly Biosciences, Inc. for worldwide rights to Assembly's microbiome GI development programs. Also, in October 2016, Allergan Plc. announced the formation of the IBS CounSEL, group of experts dedicated to improve diagnosis and management of irritable bowel syndrome (IBS) by providing support. These merger and acquisition help the companies to introduce quality treatment and expand the product line within the region. Companies are also focusing on research and development activities to get better approach to treat IBS. In this regard, in September 2017, Sucampo Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has accepted the application of supplemental new drug application (sNDA) for lubiprostone (AMITIZA) in children.


Furthermore, increasing consumer awareness about irritable bowel syndrome increase the footfall of patient in clinics and hospitals. Furthermore, increasing spending in the healthcare domain fuelling the growth of the IBS treatment market. According to the Centers for Medicare & Medicaid Services, in 2015, the U.S. healthcare spending increased by 5.8% reaching USD 3.2 trillion. In 2016, healthcare spending in North America had increased to some extent.


However, strict FDA regulations and unsatisfactory effectiveness of the treatment may hinder the growth of America's Americas Irritable bowel syndrome (IBS) treatment market during the forecast period.


America's Irritable bowel syndrome (IBS) treatment market is expected to grow at a CAGR of 9.3% during the forecast period 2017-2023.


Research Methodology


 Americas IBS treatment


Source: IBS - American Gastroenterological Association, Irritable Bowel Syndrome Association, U S Food and Drug Administration, World Health Organization, Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Companies

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segmentation                                                                                                      


The Americas Irritable bowel syndrome (IBS) treatmen market is segmented on the basis of types, drugs type, and end user.


On the basis the types, it is segmented into IBS-D, IBS-C, IBS-M.


On the basis of the drugs type, it is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron, and others.


On the basis of the end users, it is segmented into hospitals, clinics, and research laboratories.


Figure: Americas Irritable bowel syndrome (IBS) treatment market, by type, 2016 (%)


 Americas IBS treatment 1


Source: IBS - American Gastroenterological Association, Irritable Bowel Syndrome Association, U S Food and Drug Administration, World Health Organization, Directorate of Industries, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


IBS Treatment Market Key Findings



  • The Americas Irritable bowel syndrome (IBS) treatmen market is estimated at USD 1,959.5 million in 2016.

  • IBS-C is the fastest growing segment, which is projected grow at a CAGR of 9.6% during the forecast period 2017-2023.

  • Linaclotide is the fastest growing drugs type segment, which is expected to USD 1,164.8 million by 2023.

  • The United States captured the largest market of Americas and is expected to USD 2,660.9 million by 2023.


Regional Analysis


The Americas region is divided into North America and South America. North America command the largest market of IBS treatment owing to the well presence of health care structure, government support, various research and development programs, increasing sensitivity and specificity for diagnosing IBS, aware and concerned individual, and presence of well-developed clinical laboratories. Moreover, the presence of strong economic conditions, and the focus of research institutions on updating technology for new and advanced IBS treatment fuel the growth of the market in this region. Also, the countries in this region have multiple companies that are involved in the IBS treatment business. North America is further divided into the U.S. and Canada. Both of these countries have good economic growth and a great standard of living. According to a report published by the International Foundation for Functional Gastrointestinal Disorders, in 2016, functional gastrointestinal (GI) and motility disorders are the most common GI disorders which accounted for 1 in 4 people or more in the United States.


IBS Treatment Market Key Players


Some of the key players in this Americas Irritable bowel syndrome (IBS) treatment market are Allergan Plc (Ireland), Sucampo Pharmaceuticals (U.S.), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Abbott Laboratories (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Ardelyx, Inc. (U.S.), Nestle (Switzerland), Sebela Pharmaceuticals (Ireland), Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (U.K), Ipsen (France), Novartis AG (Switzerland), Takeda Pharmaceutical Company Ltd (Japan), Synthetic Biologics, Inc. (U.S.), Protagonist Therapeutics Inc. (U.S.), Pfizer Inc (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), Innovate Biopharmaceuticals (U.S.), 4D pharma plc (U.K).



Frequently Asked Questions (FAQ) :


Irritable bowel syndrome (IBS) treatment market projected to grow at approximately 9.3% CAGR during the assessment period (2020-2027).

The IBS-C segment by types and the linaclotide segment by drugs holds the majority shares in the global irritable bowel syndrome (IBS) treatment market.

Increasing prevalence and availability of effective therapeutics to treat the condition are major tailwinds pushing the growth of the global irritable bowel syndrome (IBS) treatment market.

North America holds the largest share in the global irritable bowel syndrome (IBS) treatment market, followed by Europe and the Asia Pacific, respectively.

Sucampo Pharmaceuticals (U.S.), Allergan Plc (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals (Canada), Astellas Pharma Inc. (Japan), Abbott Laboratories (U.S.), Ardelyx, Inc. (U.S.), Synergy Pharmaceuticals, Inc. (U.S.), Nestle (Switzerland), Probi (Sweden), Sebela Pharmaceuticals (Ireland), Alfasigma USA, Inc. (Italy), AstraZeneca (U.K), RedHill Biopharma Ltd. (Israel), Ipsen (France), Takeda Pharmaceutical Company Ltd (Japan), Novartis AG (Switzerland), Synthetic Biologics, Inc. (U.S.), Pfizer Inc (U.S.), Protagonist Therapeutics Inc. (U.S.), Lexicon Pharmaceuticals, Inc. (U.S.), 4D pharma plc (U.K), and Innovate Biopharmaceuticals (U.S.), are some of the top players operating in the global irritable bowel syndrome (IBS) treatment market.